Q4 2024 · 13F-HR
TCG Crossover Management, LLCholdings as filed
Filed 2025-02-14 · accession 0001214659-25-002888
$1.02B
Reported value
38
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG ONCOLOGY INC | $105.3M | 10.3% | 3,670,206 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $62.4M | 6.10% | 2,650,150 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $56.4M | 5.51% | 2,452,138 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $54.3M | 5.31% | 6,964,375 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $48.4M | 4.73% | 2,890,816 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $45.4M | 4.44% | 5,319,148 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $44.9M | 4.38% | 2,801,763 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA AMERICAN DEPOSITARY SHARES | $44.3M | 4.33% | 6,056,596 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $38.0M | 3.71% | 12,362,205 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $33.2M | 3.24% | 10,736,000 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $32.7M | 3.20% | 1,501,624 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $30.9M | 3.02% | 486,957 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $30.4M | 2.97% | 2,470,265 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $30.0M | 2.93% | 1,477,593 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $28.8M | 2.82% | 1,063,000 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $27.6M | 2.70% | 1,989,103 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $26.6M | 2.60% | 3,572,335 | Common | SOLE |
| 171757206 | CDTX | Cidara Therapeutics, Inc. | $26.1M | 2.55% | 1,005,901 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $25.8M | 2.52% | 2,505,424 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $24.7M | 2.42% | 550,000 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $24.7M | 2.41% | 2,761,861 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $24.7M | 2.41% | 5,250,000 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $20.9M | 2.04% | 3,033,560 | Common | SOLE |
| 75382E109 | — | RAPT Therapeutics, Inc. | $19.8M | 1.93% | 13,135,260 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $17.6M | 1.72% | 4,643,812 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS LTD | $14.6M | 1.43% | 3,858,000 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $12.4M | 1.21% | 1,423,642 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $12.0M | 1.17% | 650,000 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $11.4M | 1.11% | 1,145,538 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $10.1M | 0.99% | 584,955 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $8.7M | 0.85% | 550,000 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $8.4M | 0.82% | 1,796,482 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $7.9M | 0.77% | 2,676,580 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $5.9M | 0.58% | 2,240,809 | Common | SOLE |
| 640268108 | NKTREUR | NEKTAR THERAPEUTICS | $3.7M | 0.36% | 4,000,000 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $3.6M | 0.35% | 483,000 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $692,467 | 0.07% | 316,195 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $197,025 | 0.02% | 86,795 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.